Stryker (NYSE:SYK) Price Target Cut to $379.00 by Analysts at BTIG Research

Stryker (NYSE:SYK) had its price target reduced by BTIG Research from $397.00 to $379.00 in a research note issued to investors on Friday, MarketBeat reports. They currently have a buy rating on the medical technology company’s stock.

SYK has been the topic of several other research reports. Leerink Partners started coverage on shares of Stryker in a research note on Monday, April 13th. They set an “outperform” rating and a $410.00 target price on the stock. Barclays reaffirmed an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. The Goldman Sachs Group lowered their target price on shares of Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Finally, Citigroup reduced their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $401.43.

Stryker Price Performance

SYK traded down $19.70 on Friday, hitting $295.43. 4,518,113 shares of the company’s stock were exchanged, compared to its average volume of 1,836,681. Stryker has a fifty-two week low of $294.55 and a fifty-two week high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $345.67 and a 200-day moving average price of $356.95. The stock has a market cap of $113.15 billion, a price-to-earnings ratio of 35.17, a P/E/G ratio of 1.84 and a beta of 0.92.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.74% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the firm earned $2.84 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker will post 14.91 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Stryker’s payout ratio is currently 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new position in Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the fourth quarter valued at about $27,000. Finally, DJE Kapital AG acquired a new position in Stryker in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.